Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen‐Deprivation Therapy

[1]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[2]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[3]  I. Svane,et al.  Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer. , 2016, Clinical genitourinary cancer.

[4]  S. Hitier,et al.  First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry. , 2016, Urologic oncology.

[5]  K. Akakura,et al.  Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. , 2015, The Journal of urology.

[6]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[7]  D. Dearnaley,et al.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Heijboer,et al.  Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. , 2012, The Journal of urology.

[9]  C. Magi-Galluzzi,et al.  Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. , 2008, Urology.

[10]  A. Orsola,et al.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. , 2007, The Journal of urology.

[11]  Y. Ishikawa,et al.  Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. , 2007, European urology.

[12]  M. Kattan,et al.  Testosterone as a predictor of pathological stage in clinically localized prostate cancer. , 2005, The Journal of urology.

[13]  T. Ichikawa,et al.  Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. , 2005, European urology.

[14]  Jason C. Massengill,et al.  Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. , 2003, The Journal of urology.

[15]  G. Kramer,et al.  High‐grade prostate cancer is associated with low serum testosterone levels , 2001, The Prostate.

[16]  M. Resnick,et al.  Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. , 2000, Urology.

[17]  W. DeWolf,et al.  Is low serum free testosterone a marker for high grade prostate cancer? , 2000, The Journal of urology.

[18]  R. Schiavi,et al.  Pituitary-gonadal function during sleep in healthy aging men , 1992, Psychoneuroendocrinology.

[19]  J. Carles,et al.  Free Testosterone During Androgen Deprivation Therapy Predicts Castration‐Resistant Progression Better Than Total Testosterone , 2017, The Prostate.